1. AbbVie. Humira (adalimumab) injection [prescribing information]. North Chicago: AbbVie Inc; 2015.
2. Tebbey PW, Varga A, Naill M, Clewell J, Venema J. Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab). MAbs. 2015;7(5):805–11.
3. European Medicines Agency. Guideline on similar biological medicinal products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf . Accessed 7 July 2016.
4. WHO Expert Committee on Biological Standardization. Guidelines on evaluation of similar biotherapeutic products (SBPs). WHO Technical Report Series no. 977. Annex 2. 2013. http://who.int/biologicals/publications/trs/areas/biological_therapeutics/TRS_977_Annex_2.pdf . Accessed 7 July 2016.
5. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product. Guidance for industry. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291134.pdf . Accessed 7 July 2016.